Klivira
Request demo

Automating Trikafta Prior Authorization for Cardiology Practices

Cardiology practices navigate a complex landscape of prior authorizations for both high-cost procedures and specialty medications, including the administrative demands of Trikafta prior authorization for cardiology patients.

Managing prior authorizations in cardiology presents unique challenges, from advanced cardiac imaging to interventional procedures and specialty cardiovascular drugs. Simultaneously, practices must process PAs for high-volume medications like Trikafta, which require diligent attention across diverse payer requirements. Klivira offers an automated solution to streamline these critical workflows.

The Dual Burden: Cardiology PA and Specialty Drug Management

Cardiology is among the highest-volume specialties for prior authorizations, encompassing advanced cardiac imaging, interventional procedures, and a growing list of specialty cardiovascular drugs. This administrative load, coupled with the need to process PAs for high-volume medications like Trikafta, diverts clinical staff from direct patient care and can lead to significant treatment delays.

High-Volume Prior Authorization Categories in Cardiology

  • Advanced cardiac imaging (stress echo, nuclear stress, cardiac MRI/CT, PET cardiac viability)
  • Cardiac catheterization (diagnostic cath, percutaneous coronary intervention, structural-heart procedures)
  • Electrophysiology procedures (ICDs, CRT, pacemakers, ablation)
  • Specialty cardiovascular drugs (PCSK9 inhibitors, sacubitril/valsartan, SGLT2 inhibitors for HF, mavacamten)

Addressing Trikafta Prior Authorization Challenges

Trikafta is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. While not a primary cardiology medication, practices may encounter its PA requirements when managing patients with complex comorbidities. Efficient processing is crucial to ensure timely access for eligible patients, minimizing administrative overhead for cardiology teams.

Key Documentation for Cardiology Prior Authorizations

  • ACC/AHA guidelines for procedures and drug indications (e.g., ejection fraction, NYHA functional class)
  • ACR Appropriateness Criteria for advanced cardiac imaging (e.g., pre-test probability, prior imaging history)
  • Optimal medical therapy duration for device implants (e.g., ICD/CRT eligibility)
  • Symptoms and functional limitations for interventional procedures

Klivira's Solution for Cardiology and Specialty Drug PAs

Klivira's platform is designed to automate the diverse prior authorization needs of cardiology practices. This includes intelligent routing for specialty benefit-management vendors (e.g., Carelon MBM, eviCore successor vendors, NIA/Magellan) for imaging, as well as streamlined workflows for specialty drugs and device PAs. Our system integrates with existing EMRs to reduce manual data entry and accelerate approval times.

Mitigating Common Cardiology PA Denials

Klivira helps mitigate common cardiology PA denials such as inappropriate use criteria for advanced imaging, step therapy requirements for procedures or drugs, and documentation gaps for device eligibility (e.g., ejection fraction, NYHA class). By ensuring complete and accurate submissions aligned with payer policies, we aim to improve first-pass approval rates across the cardiology service line.

Frequently asked questions

How does Klivira handle the varied documentation for cardiology prior authorizations?

Klivira's platform incorporates policy logic informed by guidelines like ACC/AHA and ACR Appropriateness Criteria. It intelligently identifies required documentation, such as EF for ICDs or prior imaging for cath, and prompts for its inclusion, ensuring comprehensive submissions for cardiology procedures and related specialty drugs.

Can Klivira manage prior authorizations routed through specialty benefit-management vendors for cardiology?

Yes, Klivira automatically identifies whether a cardiology PA request, particularly for advanced imaging, routes to a specialty benefit-management vendor (e.g., Carelon MBM, eviCore successor, NIA/Magellan) or directly to a payer. It then facilitates submission through the correct channel, streamlining a common workflow constraint.

How does Klivira support prior authorization for high-volume specialty drugs like Trikafta?

Klivira centralizes the prior authorization process for all specialty drugs, including high-volume targets like Trikafta. Our system manages payer-specific requirements and step-therapy logic, ensuring that all necessary documentation is compiled and submitted efficiently, regardless of the drug's primary specialty.

What are common reasons for cardiology PA denials that Klivira helps address?

Klivira helps mitigate common cardiology PA denials such as inappropriate use criteria for advanced imaging, step-therapy requirements, and documentation gaps for device eligibility (e.g., ejection fraction, NYHA class). By ensuring complete and accurate submissions aligned with payer policies, we aim to improve first-pass approval rates.

Does Klivira integrate with our existing EMR for cardiology PA workflows?

Klivira offers robust EMR integration capabilities, including SMART on FHIR, to seamlessly pull patient demographics, clinical notes, and diagnostic results directly into PA requests. This eliminates manual data entry, speeds up the PA process for cardiology procedures and drugs, and reduces errors.

Related coverage

Other trikafta prior authorization by payer

Other trikafta prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo